Olon Expands ADC Platform With New Biologics Capacity in France
Olon is expanding its ADC platform at its Saint-Julien, France site while strengthening links with its Rodano, Italy facility. The CDMO is adding a dedicated
ABIONYX Pharma and OLON Enter Strategic CER-001 Manufacturing Partnership
ABIONYX Pharma and OLON have entered a strategic manufacturing partnership to prepare CER-001 for regulatory approval and potential commercial supply. The collaboration will initially focus
Alvotech and LOTTE Biologics Sign Long-Term Manufacturing Partnership
Alvotech and LOTTE Biologics have announced a long-term strategic manufacturing partnership to support global supply of multiple antibody biosimilar products. Under the agreement, LOTTE Biologics
AstraZeneca Opens 570,000-Square-Foot R&D Center in Cambridge
AstraZeneca has opened a new global strategic research and development (R&D) center in Kendall Square, Cambridge, Massachusetts. The 570,000-square-foot facility is intended to bring together
Terumo Launches K-Pack Embrace Active Safety Needle Globally
Terumo Corporation has announced the global commercial launch of its K-Pack Embrace active safety needle, a safety injection needle designed for automated co-packing processes. The
ACG Introduces RecycloPod PP Ultra With Moisture and Oxygen Barriers
ACG has launched RecycloPod PP Ultra, a polypropylene-based blister packaging system designed to combine moisture and oxygen barrier protection with design for recyclability. The product
Charles River Laboratories Launches Apollo Orchestrate for Digital GMP Testing
Charles River Laboratories International and Autolomous have introduced Apollo Orchestrate, a new capability within Charles River’s Apollo platform designed to connect and digitize laboratory execution.
Quantum BioPharma Signs Phase 2 Study Start-Up Agreement With Thermo Fisher’s PPD CRO for First-in-Class MS Candidate Lucid-MS
Quantum BioPharma Ltd. (NASDAQ: QNTM; FRA: 0K91), a biopharmaceutical company focused on developing innovative therapies and technologies, announced on October 6, 2026, from Toronto, Canada, that
Upperton Unveils New Brand Identity for End-to-End CDMO
Upperton has unveiled a new brand identity at CPHI Milan as it positions itself as a specialist, end-to-end contract development and manufacturing organization (CDMO) focused
Ofichem to Acquire Kinentia Biosciences and Expand Into U.S. Market
Ofichem has signed an agreement to acquire Kinentia Biosciences, a Drug Substance CDMO based in Rensselaer, New York. Completion of the transaction remains subject to